CHATSWORTH, Calif., Feb. 21, 2012 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of high-value personalized diagnostics testing services today announced that its Iris Personalized Medicine Group has launched its NADiA®ProsVue™ prognostic cancer test in the United States and is accepting blood samples for analysis at its CLIA certified molecular diagnostics laboratory.
